Exo-miR-150 targets IGF2BP1 (Xu et al., 2020b), Exo-miR-195 targets KIF4A (Lu et al., 2022), Exo-miR-206 targets NRSN2 (Keremu et al., 2022), and RGD-Exo targets Rad18 (Du et al., 2022), along with other pathways that impede the evolution of osteosarcoma. Here, IGF2BP1 is linked to osteosarcoma.